Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Rasigiline · 1 trial · 1 indication
The ratio of Tyramine pressor response (Tyr30) in Period 1 over Tyr30 in Period 3.
| Arm | Type | Description |
|---|---|---|
| Rasagiline group | EXPERIMENTAL | Participants will receive rasagiline once daily (QD) for 14 days from Days 59 to 72. |
| Phenelzine group | EXPERIMENTAL | Participants will receive phenelzine twice daily (BID) for 14 days from Days 59 to 72. |
| Ozanimod Therapeutic group | EXPERIMENTAL | Participants will receive ozanimod QD for 65 days (including the initial 7-day dose escalation) from Days 8 to 72. |
| Ozanimod Supra-therapeutic group | EXPERIMENTAL | Participants will receive ozanimod QD for 65 days (including the initial 10-day dose escalation) from Days 8 to 72. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive matched appropriate placebos from Days 8 to 72. |
| Name | Type | Description |
|---|---|---|
| Placebo | OTHER | Placebo |
| Rasigiline | DRUG | Rasigiline |
| Phenelzine | DRUG | Phenelzine |
| Ozanimod | DRUG | Ozanimod |
Inclusion Criteria: Participants must satisfy the following criteria to be enrolled in the study: 1. Be a male or non-pregnant, non-lactating female, 25 to 55 years of age, inclusive, at the time of signing the informed consent form. 2. Must understand and voluntarily sign an informed consent form...
Rasigiline is an investigational small molecule being developed by Bristol-Myers Squibb Company (BMY). It is currently in Phase 1 clinical development. The drug has been studied in healthy volunteers, and its therapeutic area is classified as Other.
Rasigiline is being studied for use in healthy volunteers. It has not been approved for any medical condition and is still in early clinical development. The drug is currently in Phase 1 trials, with one completed study involving healthy adult participants.
Rasigiline is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting clinical trials to evaluate the drug in healthy volunteers. Rasigiline is currently in Phase 1 development.
Rasigiline is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the drug is not currently in active trials.
Rasigiline has been studied in one clinical trial, NCT04978298, titled "Study to Evaluate the Pressor Effect of Oral Tyramine During Ozanimod Treatment in Healthy Adult Participants." This Phase 1, placebo-controlled, double-blind, randomized study enrolled 128 healthy volunteers in the United States and has been completed.